Is there any clinically relevant cannabinoid-induced analgesia?

Pharmacology

Volumn 89, Issue 5-6, 2012, Pages 237-246

  Kraft, Birgit ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Analgesia; Cannabinoids; Chronic and acute pain

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AJULEMIC ACID; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR; CANNABIS; CODEINE; DIAZEPAM; DIHYDROCODEINE; DRONABINOL; ENDOCANNABINOID; GABAPENTIN; MORPHINE; NABILONE; NABIXIMOLS; PARACETAMOL; PLACEBO;

ADDICTION; ANALGESIA; ARTICLE; AVULSION INJURY; BRACHIAL PLEXUS AVULSION; CANNABIS SMOKING; CHRONIC PAIN; COGNITIVE DEFECT; COPING BEHAVIOR; DIZZINESS; DROWSINESS; HUMAN; HYPOTENSION; HYPOTHERMIA; MOOD; MULTIPLE SCLEROSIS; NEOPLASM; NEUROPATHIC PAIN; NEUROPATHY; NOCICEPTIVE PAIN; NONHUMAN; PAIN; PAIN THRESHOLD; POLYNEUROPATHY; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SLEEP; SPINAL PAIN; TACHYCARDIA; XEROSTOMIA;

ACUTE PAIN; ANALGESIA; ANALGESICS; ANIMALS; CANNABINOIDS; CHRONIC PAIN; HUMANS; SPECIES SPECIFICITY;

EID: 84859707077     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000337376     Document Type: Article

References (89)

1. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-613.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
3. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
4. Demuth DG, Molleman A: Cannabinoid signalling. Life Sci 2006; 78: 549-563.
5. Guo J, Ikeda SR: Endocannabinoids modulate N-type calcium channels and G-proteincoupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. Mol Pharmacol 2004; 65: 665-674.
6. Sharir H, Abood ME: Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 2010; 126: 301-313.
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-1949.
8. Herkenham M, Lynn AB, Johnson MR, Melvin LS, DeCosta BR, Rice KC: Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1999; 11: 563-583.
9. Hohmann AG, Briley EM, Herkenham M: Pre-and postsynaptic distribution of cannabinoid and opioid receptors in rat spinal cord. Brain Res 1999; 822: 17-25.
10. Wenger T, Fernandez-Ruis JJ, Ramos JA: Immunohistochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituary gland. J Neuroendocrinol 1999; 11 873-878.
11. Lichtman AH, Martin BR: Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Ther 1991; 258: 517-523.
12. Fride E, Mechoulam R: Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993; 231: 313-314.
13. Lichtman AH, Martin BR: The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav 1997; 57: 7-12.
14. Richardson JD, Aanonsen L, Hargreaves KM: Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998; 345: 145-153.
15. Richardson JD, Kilo S, Hargreaves KM: Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75: 111-119.
16. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R: Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007; 10: 870-879.
17. Liu C, Walker JM: Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain. J Neurophysiol 2006; 96: 2984-2994.
18. Lim G, Sung B, Ji RR, Mao J: Upregulation of spinal cannabinoid-1- receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain 2003; 105: 275-283
19. Calignano A, La Rana G, Giuffrida A, Piomelli D: Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-281.
20. Richardson JD, Aanonsen L, Hargreaves KM: Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 1998; 18: 451-457.
21. Wilkinson JD, Kendall DA, Ralevic V: Delta 9-tetrahydrocannabinol inhibits electrically-evoked CGRP release and capsaicin-sensitive sensory neurogenic vasodilatation in the rat mesenteric arterial bed. Br J Pharmacol 2007; 152: 709-716.
22. Amaya F, Shimosato G, Kawasaki Y, Hashimoto S, Tanaka Y, Ji RR, Tanaka M: Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 2006; 124: 175-183.
23. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG: Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 2007; 150: 153-163.
24. Potenzieri C, Brink TS, Pacharinsak C, Simone DA: Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation. J Neurophysiol 2008; 100: 2794-2806.
25. Johanek LM, Simone DA: Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain 2004; 109: 432-442.
26. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, James I: The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain2001; 92: 91-100.
27. Guerrero AV, Quang P, Dekker N, Jordan RC, Schmidt BL: Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. Neurosci Lett 2008; 433: 77-81.
28. Potenzieri C, Harding-Rose C, Simone DA: The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. Brain Res 2008; 1215: 69-75.
29. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS: The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide invisceral and somatic inflammatory pain. Pain 1998; 76: 189-199.
30. Valenzano KJ, Tafesse L, Lee G, Harrison JE, Boulet JM, Gottshall SL, Mark L, Pearson MS, Miller W, Shan S, Rabadi L, Rotshteyn Y, Chaffer SM, Turchin PI, Elsemore DA, Toth M, Koetzner L, Whiteside GT: Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005; 48: 658-672.
31. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan TP Jr: Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 2003; 99: 955-960.
32. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP Jr: CB2 cannabinoid receptor mediation of antinociception. Pain 2006; 122: 36-42.
33. Brownjohn PW, Ashton JC: Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury. Neuroscience 2012; 203: 180-193.
34. Khasabova IA, Gielissen J, Chandiramani A, Harding-Rose C, Odeh DA, Simone DA, Seybold V: CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol 2011; 22: 607-616.
35. Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG: Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav 2011; 98: 493-502.
36. Anand U, Otto WR, Anand P: Sensitization of capsaicin and icilin responses in oxaliplatin treated adult rat DRG neurons. Mol Pain 2010; 6: 82.
37. Curto-Reyes V, Llames S, Hidalgo A, Menéndez L, Baamonde A: Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. Br J Pharmacol 2010; 160: 561-573.
38. Jhaveri MD, Elmes SJ, Richardson D, Barrett DA, Kendall DA, Mason R, Chapman V: Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats. Eur J Neurosci 2008; 27: 1722-1730.
39. Romero-Sandoval A, Eisenach JC: Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 2007; 106: 787-794.
40. Su TF, Zhang LH, Peng M, Wu CH, Pan W, Tian B, Shi J, Pan HL, Li M: Cannabinoid CB2 receptors contribute to upregulation of beta-endorphin in inflamed skin tissues by electroacupuncture. Mol Pain 2011; 7: 98.
41. Yamamoto W, Mikami T, Iwamura H: Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 2008; 583: 56-61.
42. Hsieh CG, Pa Mi, Chandran P, Hooker BA, Zhu CZ, Salyers AK, Wensink EJ, Zhan C, Carroll WA, Dart MJ, Yao BB, Honore P, Meyer MD: Central and peripheral sites of action for CB(2) receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 2011; 162: 428-440.
43. Cox ML, Haller VL, Welch SP: The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. Eur J Pharmacol 2007; 570: 50-56.
44. Merriam FV, Wang ZY, Guerios SD, Bjorling DE: Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. Neurosci Lett 2008; 445: 130-113.
45. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R: The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003; 105: 79-78.
46. Kraft B, Frickey NA, Kaufmann RM, Reif M, Frey R, Gustorff B, Kress HG: Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008; 109: 101-110.
47. Wallace M, Schulteis G, Atkinson HJ, Wolfson T, Lazzaretto MS, Bentlea H, Gouaux B, Abramson I: Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007; 107: 785-796.
48. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ: Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003; 106: 169-172.
49. Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S: A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006; 104: 1040-1046.
50. Beaulieu P: Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006; 53: 769-765.
51. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B: The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-534.
52. Martín-Sánchez E, Furukawa TA, Taylor J, Martin JL: Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009; 10: 1353-1368.
53. Rog D, Young CA: Randomised controlled trial of cannabis-based medicinal extracts in the treatment of neuropathic pain due to multiple sclerosis. Multiple Sclerosis ECTRIMS 2003;S9: 25.
54. Svendsen KB, Jensen TS, Bach FW: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329: 253.
55. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebocontrolled trial. Lancet 2003; 362: 1517-1526.
56. Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH: Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009; 34: 672-680.
57. Abrams DI, Jay CA, Shade SB, Visozo H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL: Cannabis in painful HIV-associated sensory neuropathy. Neurology 2007; 68: 515-521.
58. Berman JS, Symonds C, Birch R: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 2004; 112: 299-306.
59. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008; 9: 506-521.
60. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D: Sativex successfully treats neuropathic pain characterized by allodynia: a randomised, doubleblind, placebo-controlled clinical trial. Pain 2007; 133: 210-220.
61. Maurer M, Henn V, Dittrich A, Hofmann A: Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 1990; 240: 1-4.
62. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290: 1757-1762.
63. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D: Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 2004; 8: 173-177.
64. Hagenbach U, Luz S, Ghafoor N, Berger JM, Grotenhermen F, Brenneisen R, Mäder M: The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007; 45: 551-562.
65. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D: Sativex successfully treats neuropathic pain characterized by allodynia: a randomised, doubleblind, placebo-controlled clinical trial. Pain 2007; 133: 210-220.
66. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M: Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 2003; 139: 258-256.
67. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D: Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic ain: randomised, crossover, double blind study. BMJ 2008; 336: 199-201.
68. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.J Pain 2008; 9: 506-521.
69. Selvarajah D, Gandhi R, Emery CJ, Tesfaye S: Randomized placebo-controlled doubleblind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care 2010; 33: 128-130.
70. Rintala DH, Fiess RN, Tan G, Holmes SA, Bruel BM: Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Am J Phys Med Rehabil 2010; 89: 840-848.
71. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP: Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182:E694-701.
72. Bestard JA, Toth CC: An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract 2011; 11: 353-368.
73. Noyes R Jr, Brunk SF, Avery DA, Canter AC: The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18: 84-89.
74. Noyes R Jr, Brunk SF, Baram DA, Canter A: Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15: 139-143.
75. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ: Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003; 02: 211-216.
76. Blake DR, Robson P, Ho M, Jubb RW, Mc-Cabe CS: Preliminary assessment of the efficacy, tolerability and safety of a cannabisbased medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006; 45: 50-52.
77. Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R: Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006; 22: 1269-1276.
78. Berlach DM, Shir Y, Ware MA: Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med 2006; 7: 25-29 .
79. Skrabek RQ, Galimova L, Ethans K, Perry D: Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9: 164-173.
80. Ware MA, Fitzcharles MA, Joseph L, Shir Y: The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110: 604-610.
81. Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M: Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol 2008; 6: 119-124.
82. Lynch ME, Campbell F: Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 2011; 72: 735-744.
83. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, Jamison RN: Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008; 9: 254-264.
84. Smith PA, Selley DE, Sim-Selley LJ, Welch SP: Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 2007; 571: 129-137.
85. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 2010; 39: 167-179.
86. Crean RD, Crane NA, Mason BJ: An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011; 5: 1-8.
87. Bachs L, Morland H: Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001; 124: 200-203.
88. Sidney S: Cardiovascular consequences of marijuana use. J Clin Pharmacol 2002; 42(11 suppl):64S-70S.
89. Mateo I, Pinedo A, Gomez-Beldarrain M, Basterretxea JM, Garcia-Monco JC: Recurrent stroke associated with cannabis use. J Neurol Neurosurg Psychiatry 2005; 6: 435-437.